Journal of Anesthesia

, Volume 25, Issue 6, pp 953–954 | Cite as

Can sugammadex encapsulation eliminate the antigenic activity of aminosteroidal neuromuscular blocking agent?

Letter to the Editor
First Online:
Received:
Accepted:

Keywords

Sugammadex Neuromuscular blocking agents Anaphylaxis 
This is a preview of subscription content, log in to check access.

References

  1. 1.
    Dewachter P, Mouton-Faivre C, Emala CW. Anaphylaxis and anesthesia: controversies and new insights. Anesthesiology. 2009;111:1141–50.PubMedCrossRefGoogle Scholar
  2. 2.
    Mertes PM, Laxenaire MC, Alla F. Anaphylactic and anaphylactoid reactions occurring during anesthesia in France in 1999–2000. Anesthesiology. 2003;99:536–45.PubMedCrossRefGoogle Scholar
  3. 3.
    McDonnell NJ, Pavy TJ, Green LK, Platt PR. Sugammadex in the management of rocuronium-induced anaphylaxis. Br J Anaesth. 2011;106:199–201.PubMedCrossRefGoogle Scholar
  4. 4.
    Jones PM, Turkstra TP. Mitigation of rocuronium-induced anaphylaxis by sugammadex: the great unknown. Anaesthesia. 2010;65:89–90.PubMedCrossRefGoogle Scholar
  5. 5.
    Leysen J, Bridts CH, De Clerck LS, Ebo DG. Rocuronium-induced anaphylaxis is probably not mitigated by sugammadex: evidence from an in vitro experiment. Anaesthesia. 2011;66:526–7.PubMedCrossRefGoogle Scholar

Copyright information

© Japanese Society of Anesthesiologists 2011

Authors and Affiliations

  1. 1.Department of Anesthesiology and Critical Care MedicineKochi Medical SchoolNankokuJapan

Personalised recommendations